<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465904</url>
  </required_header>
  <id_info>
    <org_study_id>51401</org_study_id>
    <nct_id>NCT03465904</nct_id>
  </id_info>
  <brief_title>A Phase III Trial of e-TNS for the Acute Treatment of Migraine</brief_title>
  <acronym>TEAM</acronym>
  <official_title>A Phase III Randomized, Double-blind, Sham-controlled Trial of e-TNS for the Acute Treatment of Migraine (The TEAM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cefaly Technology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cefaly Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to have Phase III evidences of the efficacy of the
      Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This
      randomized, double-blind, sham-controlled trial will study the abortive treatment of migraine
      using the Cefaly® Abortive Program device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to have Phase III evidences of the efficacy of the
      Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack, as
      triptans are generally used. That is to say having randomized, double-blind, sham-controlled
      data of the efficacy and safety of the Cefaly® Abortive Program device in the abortive
      treatment of acute migraine as measured by 2-hour pain freedom, pain relief and
      migraine-associated symptoms freedom, plus evolution of these measurements for 24 hours after
      the beginning of the treatment session.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Actual">January 11, 2019</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Freedom at 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the beginning of the e-TNS session.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Most Bothersome Migraine-associated Symptom Freedom at 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients with absence, at 2 hours after the beginning of the e-TNS session, of the most bothersome migraine-associated symptom identified at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief at 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to a mild headache or to no headache (Grade 1 or 0) at 2 hours after the beginning of the e-TNS session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Absence of Photophobia, Phonophobia, Nausea, Vomiting at 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <description>The percentage of patients with absence of photophobia, phonophobia, nausea, vomiting at 2 hours after the beginning of the e-TNS session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication Between 2 and 24 Hours</measure>
    <time_frame>2-24 hours</time_frame>
    <description>The percentage of patients who took anti-migraine rescue medication between 2 and 24 hours after the beginning of the e-TNS session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Pain Freedom at 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>The percentage of patients having no headache (Grade 0) at 2 hours, with no use of anti-migraine rescue medication and no relapse of headache pain within the 24 hours after the beginning of the e-TNS session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Pain Relief at 24 Hours</measure>
    <time_frame>2-24 hours</time_frame>
    <description>The percentage of patients having mild or no headache (Grade 1 or 0) at 2 hours, with no use of anti-migraine rescue medication and no relapse of headache pain within the 24 hours after the beginning of the e-TNS session.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">601</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verum Cefaly® Abortive Program device</intervention_name>
    <description>The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Cefaly® Abortive Program device</intervention_name>
    <description>The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18 to 65 on the day of signing the informed consent form

          2. ≥ 1-year history of migraine with or without aura according to the diagnostic criteria
             listed in International Classification of Headache Disorders (ICHD)-3 beta (2013)
             section 1, migraine, with the exception of aura without headache, hemiplegic migraine
             and brainstem aura migraine

          3. Migraine onset before the age of 50

          4. Having between 2 and 8 moderate or severe migraine attacks (Grade 2 or 3) per month in
             each of the two months prior to screening

          5. Patient understands the study procedures, alternative treatments available, and
             voluntarily agrees to participate in the study by giving written informed consent

          6. Patient is able to read and understand the written information (instruction sheet,
             paper diary and Adverse Events reporting form)

        Exclusion Criteria:

          1. Patient has difficulty distinguishing his/her migraine attacks from tension-type
             headaches

          2. Patient has more than 15 headache days per month

          3. Patient having received supraorbital nerve blocks in the prior 4 months

          4. Patient having received Botox treatment in the prior 4 months

          5. Modification of a migraine prophylaxis treatment in the previous 3 months

          6. Diagnosis of other primary headache disorders, except rare (&lt; 4) tension-type
             headaches per month

          7. Diagnosis of secondary headache disorders including Medication Overuse Headache (MOH)

          8. Patient abusing opioids or user of recreational or illicit drugs or having had a
             recent history (within the last year) of drug or alcohol abuse or dependence

          9. Implanted metallic or electronic device in the head

         10. Cardiac pacemaker or implanted or wearable defibrillator

         11. Patient having had a previous experience with the Cefaly® device

         12. Migraine Aura without headache

         13. Patient is currently participating or has participated in a study with an
             investigational compound or device in the last 30 days before the screening visit
             (Visit 1)

         14. Patient not having the ability to use appropriately the device and/or to perform
             himself/herself or bear the first 20-minute stimulation session during the training
             test session at the study site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deena Kuruvilla, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Savannah Neurology)</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research (Rockville Neurology)</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <results_first_submitted>June 5, 2019</results_first_submitted>
  <results_first_submitted_qc>June 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2019</results_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03465904/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Verum</title>
          <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
        </group>
        <group group_id="P2">
          <title>Sham</title>
          <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="303"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible for mITT analysis</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Verum</title>
          <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
        </group>
        <group group_id="B2">
          <title>Sham</title>
          <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="209"/>
            <count group_id="B2" value="237"/>
            <count group_id="B3" value="446"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="209"/>
                    <count group_id="B2" value="237"/>
                    <count group_id="B3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.43" spread="11.54"/>
                    <measurement group_id="B2" value="40.98" spread="11.65"/>
                    <measurement group_id="B3" value="40.71" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="209"/>
                    <count group_id="B2" value="237"/>
                    <count group_id="B3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="369"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="209"/>
                    <count group_id="B2" value="237"/>
                    <count group_id="B3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Migraine with aura</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Migraine without aura</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Headache pain severity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="209"/>
                    <count group_id="B2" value="237"/>
                    <count group_id="B3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Moderate pain severity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe pain severity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Most Bothersome Symptom</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="209"/>
                    <count group_id="B2" value="237"/>
                    <count group_id="B3" value="446"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Nausea as MBS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Vomiting as MBS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sensitivity to light as MBS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Sensitivity to sound as MBS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Freedom at 2 Hours</title>
        <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the beginning of the e-TNS session.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Freedom at 2 Hours</title>
          <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the beginning of the e-TNS session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Most Bothersome Migraine-associated Symptom Freedom at 2 Hours</title>
        <description>The percentage of patients with absence, at 2 hours after the beginning of the e-TNS session, of the most bothersome migraine-associated symptom identified at baseline.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Most Bothersome Migraine-associated Symptom Freedom at 2 Hours</title>
          <description>The percentage of patients with absence, at 2 hours after the beginning of the e-TNS session, of the most bothersome migraine-associated symptom identified at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief at 2 Hours</title>
        <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to a mild headache or to no headache (Grade 1 or 0) at 2 hours after the beginning of the e-TNS session.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief at 2 Hours</title>
          <description>The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to a mild headache or to no headache (Grade 1 or 0) at 2 hours after the beginning of the e-TNS session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Absence of Photophobia, Phonophobia, Nausea, Vomiting at 2 Hours</title>
        <description>The percentage of patients with absence of photophobia, phonophobia, nausea, vomiting at 2 hours after the beginning of the e-TNS session.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Absence of Photophobia, Phonophobia, Nausea, Vomiting at 2 Hours</title>
          <description>The percentage of patients with absence of photophobia, phonophobia, nausea, vomiting at 2 hours after the beginning of the e-TNS session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication Between 2 and 24 Hours</title>
        <description>The percentage of patients who took anti-migraine rescue medication between 2 and 24 hours after the beginning of the e-TNS session.</description>
        <time_frame>2-24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication Between 2 and 24 Hours</title>
          <description>The percentage of patients who took anti-migraine rescue medication between 2 and 24 hours after the beginning of the e-TNS session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Pain Freedom at 24 Hours</title>
        <description>The percentage of patients having no headache (Grade 0) at 2 hours, with no use of anti-migraine rescue medication and no relapse of headache pain within the 24 hours after the beginning of the e-TNS session.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Pain Freedom at 24 Hours</title>
          <description>The percentage of patients having no headache (Grade 0) at 2 hours, with no use of anti-migraine rescue medication and no relapse of headache pain within the 24 hours after the beginning of the e-TNS session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Pain Relief at 24 Hours</title>
        <description>The percentage of patients having mild or no headache (Grade 1 or 0) at 2 hours, with no use of anti-migraine rescue medication and no relapse of headache pain within the 24 hours after the beginning of the e-TNS session.</description>
        <time_frame>2-24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Verum</title>
            <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
          </group>
          <group group_id="O2">
            <title>Sham</title>
            <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Pain Relief at 24 Hours</title>
          <description>The percentage of patients having mild or no headache (Grade 1 or 0) at 2 hours, with no use of anti-migraine rescue medication and no relapse of headache pain within the 24 hours after the beginning of the e-TNS session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The data was collected during the 24 hours following the beginning of the treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Verum</title>
          <description>2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Verum Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.</description>
        </group>
        <group group_id="E2">
          <title>Sham</title>
          <description>2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
Sham Cefaly® Abortive Program device: The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendicitis leading to appendectomy</sub_title>
                <description>This Serious Adverse Event was not related to the subject’s participation in the study and was not reportable neither to the Institutional Review Board (IRB) nor to the FDA (the subject did not apply the treatment).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear ringing</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <description>Relation to the device not suspected</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Relation to the device not suspected</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Stomach Virus</sub_title>
                <description>Relation to the device not suspected</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Forehead pain during the session</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Tooth pain</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sedative effect</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Eye watering, tears</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Restless legs</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Eyes burning</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Sensitivity to movement and touch, and pain above right eye</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Unexpected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Pain between eyes/Extreme discomfort</sub_title>
                <description>Normal sensation of the Cefaly® device but that led to treatment permanent discontinuation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin reaction</sub_title>
                <description>Expected side effect of the Cefaly® device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Itching/Tingling</sub_title>
                <description>Normal sensation of the Cefaly® device but that led to treatment permanent discontinuation</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
              <event>
                <sub_title>Burning</sub_title>
                <description>Normal sensation of the Cefaly® device but that led to treatment permanent discontinuation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="303"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period of 90 days from the time submitted to the sponsor for review. Sponsor may request:
deletion of any trade secret, proprietary, or confidential information of Sponsor
an additional 90 days to take measures to preserve its Intellectual Property rights
Sponsor's written consent is required for results communication before trial completion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Department director</name_or_title>
      <organization>CEFALY Technology</organization>
      <phone>+32 4 367 67 22</phone>
      <email>info@cefaly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

